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Background
Polymorphisms at the thiopurine S-methyltransferase
coding gene (TPMT) determine enzyme activity and as a
consequence the development of toxicity to thiopurines
Materials and methods
A total of 108 DNA samples from volunteer donors and
39 from patients with acute lymphoblastic leukemia
(ALL) were analyzed. Genomic DNA from peripheral
blood leukocytes was isolated by standard methods.
Known (wild type and polymorphic) sequenced PCR frag-
ments of the TPMT gene were used as controls. TPMT gene
fragments were amplified for exons 5, 7 and 10. PCR
products were then analyzed by denaturating high per-
formance liquid chromatography (DHPLC) for the most
frequent mutant TPMT alleles, according to the method
developed by Schaeffeler et al. on an analysis system from
Transgenomics.
Results
No elution profiles at the DHPLC analysis were different
to those already reported. The frequency of gene polymor-
phisms was 53.7% in healthy and 38.4% in the ALL pop-
ulation. However, only 17.6% of all polymorphisms
found are considered as functional, being the most fre-
quent the *3A (n = 13, 8.8%), followed by *3B (n = 5,
3.47%), *3C (n = 5, 4.6%) and *2 (n = 3, 2. 7%).
Conclusion
DHPLC is a highly sensitive, rapid and efficient method to
identify relevant TPMT gene mutations which allows the
screening for genetic variability in the TPMT gene. This is
the first analysis of the polymorphisms at this gene in a
Mestizos population. The frequency of known silent pol-
ymorphisms was higher than those reported in other
regions worldwide, but although the frequency of func-
tional polymorphism in healthy population is within the
range found in other reports, the frequency of such poly-
morphism was higher in the patients. All together, the
routine typing of TMPT polymorphisms in the patients
with ALL is being set in our Institution.
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